



LUND UNIVERSITY

Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation

Mahdavi, Jafar; Sondén, Berit; Hurtig, Marina; Olfat, Farzad O.; Forsberg, Lina; Roche, Niamh; Ångström, Jonas; Larsson, Thomas; Teneberg, Susann; Karlsson, Karl-Anders; Altraja, Siiri; Wadström, Torkel; Kersulyte, Dangeruta; Berg, Douglas E.; Dubois, Andre; Petersson, Christoffer; Magnusson, Karl-Eric; Norberg, Thomas; Lindh, Frank; Lundskog, Bertil B.; Arnqvist, Anna; Hammarström, Lennart; Borén, Thomas

Published in:
Science

DOI:
[10.1126/science.1069076](https://doi.org/10.1126/science.1069076)

2002

[Link to publication](#)

Citation for published version (APA):

Mahdavi, J., Sondén, B., Hurtig, M., Olfat, F. O., Forsberg, L., Roche, N., Ångström, J., Larsson, T., Teneberg, S., Karlsson, K.-A., Altraja, S., Wadström, T., Kersulyte, D., Berg, D. E., Dubois, A., Petersson, C., Magnusson, K.-E., Norberg, T., Lindh, F., ... Borén, T. (2002). Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. *Science*, 297(5581), 573-578. <https://doi.org/10.1126/science.1069076>

Total number of authors:
23

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

Helicobacter pylori SabA Adhesin in Persistent Infection and Chronic Inflammation

Jafar Mahdavi,^{1*} Berit Sondén,^{1*†} Marina Hurtig,^{1*} Farzad O. Olfat,^{1,2} Lina Forsberg,¹ Niamh Roche,³ Jonas Ångström,³ Thomas Larsson,³ Susann Teneberg,³ Karl-Anders Karlsson,³ Siiri Altraja,⁴ Torkel Wadström,⁵ Dangeruta Kersulyte,⁶ Douglas E. Berg,⁶ Andre Dubois,⁷ Christoffer Petersson,⁸ Karl-Eric Magnusson,⁸ Thomas Norberg,⁹ Frank Lindh,¹⁰ Bertil B. Lundskog,¹¹ Anna Arnqvist,^{1,12} Lennart Hammarström,¹³ Thomas Borén^{1‡}

Helicobacter pylori adherence in the human gastric mucosa involves specific bacterial adhesins and cognate host receptors. Here, we identify sialyl-dimeric-Lewis x glycosphingolipid as a receptor for *H. pylori* and show that *H. pylori* infection induced formation of sialyl-Lewis x antigens in gastric epithelium in humans and in a Rhesus monkey. The corresponding sialic acid-binding adhesin (SabA) was isolated with the "retagging" method, and the underlying *sabA* gene (JHP662/HPO725) was identified. The ability of many *H. pylori* strains to adhere to sialylated glycoconjugates expressed during chronic inflammation might thus contribute to virulence and the extraordinary chronicity of *H. pylori* infection.

Helicobacter pylori persistently infects the gastric mucosa of more than half of all people worldwide, causes peptic ulcer disease, and is an early risk factor for gastric cancer (1). Many *H. pylori* strains express adhesin proteins that bind to specific host-cell macromolecule receptors (2). This adherence may be advantageous to *H. pylori* by helping to stabilize it against mucosal

shedding into the gastric lumen and ensuring good access to nourishing exudate from gastric epithelium that has been damaged by the infection. The best defined *H. pylori* adhesin-receptor interaction found to date is that between the Leb blood group antigen binding adhesin, BabA, a member of a family of *H. pylori* outer membrane proteins, and the H, Lewis b (Leb), and related ABO antigens (3–5). These fucose-containing blood group antigens are found on red blood cells and in the gastrointestinal mucosa (6). Blood group-O individuals suffer disproportionately from peptic ulcer disease, suggesting that bacterial adherence to the H and Leb antigens affects the severity of infection (7). Additional *H. pylori*-host macromolecule interactions that do not involve Leb-type antigens have also been reported (8).

H. pylori is a genetically diverse species, with strains differing markedly in virulence. Strains from persons with overt disease generally carry the *cag*-pathogenicity island (*cagPAI*) (9, 10), which mediates translocation of CagA into host cells, where it is tyrosine phosphorylated and affects host cell signaling (11). Leb antigen binding is most prevalent among *cag*⁺ strains from persons with overt disease (4, 12). Separate studies using transgenic mice that express the normally absent Leb antigen suggest that *H. pylori* adherence exacerbates inflammatory responses in this model (13). Taken together, these results point to the pivotal role of *H. pylori* adherence in development of severe disease.

Leb antigen-independent binding. Earlier studies identified nearly identical *babA* genes at different *H. pylori* chromosomal loci, each potentially encoding BabA. The *babA2* gene encodes the complete adhesin, whereas *babA1* is defective because sequences encoding the translational start and signal peptide are missing (4). Our experiments began with analyses of a *babA2*-knockout mutant derivative of the reference strain CCUG17875 (hereafter referred to as 17875). Unexpectedly, this 17875 *babA2* mutant bound to gastric mucosa from an *H. pylori*-infected patient with gastritis.

A 17875 derivative with both *babA* genes inactivated (*babA1A2*) was constructed (14). This *babA1A2* mutant also adhered (Fig. 1, B and C), which showed that adherence was not due to recombination to link the silent *babA1* gene with a functional translational start and signal sequence. Pretreatment with soluble Leb antigen (structures in table S1) resulted in >80% lower adherence by the 17875 parent strain (Figs. 1E and 3C) but did not affect adherence by its *babA1A2* derivative (Figs. 1F and 3C).

In contrast to binding to infected gastric mucosa (Fig. 1, A to I), the *babA1A2* mutant did not bind to healthy gastric mucosa from a person not infected with *H. pylori* (Fig. 1, J to M), whereas the 17875 parent strain bound avidly (Fig. 1, M versus L). These results implicated another adhesin that recognizes a receptor distinct from the Leb antigen and possibly associated with mucosal inflammation.

Adherence was also studied in tissue from a special transgenic mouse that produces Leb antigen in the gastric mucosa, the consequence of expression of a human-derived α 1,3/4 fucosyltransferase (FT) (15). Strain 17875 and the *babA1A2* mutant each adhered to Leb mouse gastric epithelium (Fig. 2A, *ii* and *iii*), whereas binding of each strain to the mucosa of nontransgenic (FVB/N) mice was poor and was limited to the luminal mucus. Thus, Leb mice express additional oligosaccharide chains (glycans), possibly fucosylated, but distinct from the Leb antigen that *H. pylori* could exploit as a receptor.

sdLex antigen-mediated binding. To search for another receptor, thin-layer chromatography (TLC)-separated glycosphingolipids (GSLs) were overlaid with *H. pylori* cells and monoclonal antibodies (mAbs), as appropriate. These tests (i) showed that the *babA1A2* mutant bound acid GSLs (Fig. 2B, *iv*, lanes 2 and 4), (ii) confirmed that it did not bind Leb GSL (lane 9), (iii) showed that its binding was abrogated by desialylation (lanes 3 and 5), and (iv) revealed that it did not bind sialylated GSLs of nonhuman origin (lane 1) [table S1, numbers 2 to 5, in (16)] (indicating that sialylation per se is not sufficient for

¹Department of Odontology/Oral Microbiology, Umeå University, SE-901 87 Umeå, Sweden. ²The Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden. ³Institute of Medical Biochemistry, Göteborg University, Box 440, SE-405 30 Göteborg, Sweden. ⁴Institute of Molecular and Cell Biology, Tartu University, EE-51010 Tartu, Estonia. ⁵Department of Infectious Diseases and Medical Microbiology, Lund University, SE-223 62 Lund, Sweden. ⁶Department of Molecular Microbiology, Washington University Medical School, St. Louis, MO 63110, USA. ⁷Laboratory of Gastrointestinal and Liver Studies, Department of Medicine, USUHS, Bethesda, MD 20814–4799, USA. ⁸Department of Molecular and Clinical Medicine, Division of Medical Microbiology, Linköping University, SE-581 85 Linköping, Sweden. ⁹Department of Chemistry, Swedish University of Agricultural Sciences, SE-750 07 Uppsala, Sweden. ¹⁰IsoSep AB, Dalkärrsv. 11, SE-146 36 Tullinge, Sweden. ¹¹Department of Medical Biosciences/Clinical Cytology, Umeå University, SE-901 87 Umeå, Sweden. ¹²Department of Molecular Biology, Umeå University, SE-901 87 Umeå, Sweden. ¹³Center for Biotechnology, Karolinska Institute, Novum, SE-141 57 Huddinge, Sweden.

*These authors contributed equally to this work.

†Present address: Unité de Génétique Mycobactérienne, Institut Pasteur, 25 rue du Dr Roux, 75724 Paris Cedex 15, France.

‡To whom correspondence should be addressed. E-mail: Thomas.Boren@odont.umu.se

adherence). In addition, the binding pattern of the *babA1A2* mutant matched that of the mAb against sLex (Fig. 2B, *ii* versus *iv*), except that sLex-mono-GSL was bound more weakly by the *babA1A2* mutant than by the mAb (Fig. 2B, *iv*) and no binding to sialyl-Lewis a-GSL was detected (table S1). Thus, the *babA1A2* mutant preferably binds sialylated gangliosides, possibly with multiple Lex (fucose-containing) motifs in the core chain (thus, slower migration on TLC).

The *babA1A2*-mutant strain was next used to purify a high-affinity binding GSL from human adenocarcinoma tissue (14). The *H. pylori*-binding GSL was identified by mass spectrometry and ¹H nuclear magnetic resonance (NMR) as the sialyl-dimeric-Lewis x antigen, abbreviated as the sdiLex antigen (Fig. 2, B and C) (14).

Further tests with soluble glycoconjugates showed that the 17875-parent strain bound both sLex and Leb antigens, whereas its derivative bound only sLex (Fig. 3A). Pretreatment of the *babA1A2* mutant with sLex conjugate reduced its *in situ* adherence by more than 90% (Figs. 1I and 3C) (14) but did not affect adherence of the 17875 parent strain (Figs. 1H and 3C). Similarly, pretreatment of tissue sections with an mAb that recognizes sdiLex reduced adherence by the *babA1A2* mutant by 72% (Fig. 3E).

Titration experiments showed that the *babA1A2* mutant exhibited high affinity for the sdiLex GSLs, with a level of detection of 1 pmol (Fig. 2B, *iv*) (table S1, number 8). At least 2000-fold more (2 nmol) of the shorter sialyl-(mono)-Lewis x GSL was needed for binding (table S1, number 7). In contrast, its affinity (K_a) for soluble conjugates was similar for

mono and dimeric forms of sLex, $1 \times 10^8 M^{-1}$ and $2 \times 10^8 M^{-1}$, respectively (Fig. 3B) (16). These patterns suggest that the sialylated binding sites are best presented at the termini of extended core chains containing multiple Lewis x motifs, such as GSLs in cell membranes. Such optimization of steric presentation would be less important for soluble receptors.

The Scatchard analyses (16) also estimated that 700 sLex-conjugate molecules were bound per *babA1A2*-mutant bacterial cell (Fig. 3B), a number similar to that of Leb conjugates bound per cell of strain 17875.

Clinical isolates. A panel of 95 European clinical isolates was analyzed for sLex binding (14). Thirty-three of the 77 *cagA*⁺ strains (43%) bound sLex, but only 11% (2 out of 18) of *cagA*⁻ strains ($P < 0.000$). However, deletion of the *cagPAI* from strain G27 did not affect sLex binding, as had also been seen in studies of *cagA* and Leb-antigen binding. Out of the Swedish clinical isolates, 39% (35 out of 89) bound sLex, and the great majority of these sLex-binding isolates, 28 out of 35 (80%), also bound the Leb antigen. Fifteen of the 35 (43%) sLex-binding isolates also bound the related sialyl-Lewis a antigen (sLea) (table S1, number 6), whereas none of the remaining 54 sLex-nonbinding strains could bind to sLea. The clinical isolates SMI65 and WU12 (the isolate from the infected patient in Fig. 1, A to M) illustrate such combinations of binding modes (Fig. 3A). Of the two strains with sequenced genomes, strain J99 (17) bound sLex, sLea, and Leb antigens, whereas strain 26695 (18) bound none of them (Fig. 3A).

Binding to inflamed tissue. Gastric tissue inflammation and malignant transformation each promote synthesis of sialylated glycoconjugates (19), which are rare in healthy human stomachs (20). Immunohistochemical analysis showed that the sialylated antigens were located to the apical surfaces of the surface epithelial cells (fig. S2). To study gastric mucosal sialylation in an *H. pylori* context, gastric biopsies from 29 endoscopy patients were scored for binding by the *babA1A2* mutant and by the 17875 strain *in situ*, and for several markers of inflammation (table S2A) (14). Substantial correlations were found between *babA1A2*-mutant adherence and the following parameters: (i) levels of neutrophil (PMN) infiltration, 0.47 ($P < 0.011$); (ii) lymphocyte/plasma cell infiltration, 0.46 ($P < 0.012$); (iii) mAb staining for sLex in surface epithelial cells and in gastric pit regions, 0.52 ($P < 0.004$); and (iv) histological gastritis score, 0.40 ($P < 0.034$). In contrast, there was no significant correlation between *babA1A2*-mutant binding *in situ* and *H. pylori* density in biopsies from natural infection (0.14, $P < 0.47$), nor between any inflammatory parameter and *in situ* adherence of strain 17875 (Leb and sLex binding).




Fig. 1. The sLex antigen confers adherence of *H. pylori* to the epithelium of *H. pylori*-infected (strain WU12) human gastric mucosa (Fig. 3A). H/E staining reveals mucosal inflammation (A). The 17875 parent strain (B) and the *babA1A2* mutant (C) both adhere to the gastric epithelium. The surface epithelium stains positive (arrows) with both the Leb mAb (D) and sLex mAb (G) [As described in (14)]. The 17875 strain and *babA1A2* mutant responded differently after pretreatment (inhibition) with soluble Leb antigen [(E) and (F), respectively], or with soluble sLex antigen [(H) and (I), respectively]]. In conclusion, the Leb antigen blocked binding of the 17875 strain, whereas the sLex antigen blocked binding of the *babA1A2* mutant. H/E-stained biopsy with no *H. pylori* infection (J). No staining was detected with the sLex mAb (K). Here, strain 17875 adhered (L), in contrast to the *babA1A2* mutant (M), because noninflamed gastric mucosa is low in sialylation (K).

RESEARCH ARTICLE

The series of 29 patient biopsies was then compared to a series of six biopsies of *H. pylori*-noninfected individuals, and a considerable difference was found to be due to lower adherence of the *babA1A2* mutant ($P < 0.000$) (table S2B), whereas strain 17875 showed no difference.

Binding to infected tissue. Biopsy material from a Rhesus monkey was used to directly test the view that *H. pylori* infection stimulates expression of sialylated epithelial glycosylation patterns that can then be exploited by *H. pylori* for adherence [monkey biopsies in (14)]. This monkey (21) had been cleared of its natural *H. pylori* infection, and gastritis declined to baseline. Gastric biopsies taken at 6 months post-eradication showed expression of sLex in the gastric gland region (Fig. 4A) and no expression in the surface epithelium (Fig. 4A). In situ adherence of the *babA1A2* mutant was limited to gastric glands and was closely matched to the sLex expression pattern (Fig. 4B). No specific adherence to the surface epithelium was seen (Fig. 4B).

At 6 months post-therapy, this gastritis-free animal had been experimentally infected with a cocktail of *H. pylori* strains, of which the J166 strain (a *cagA*-positive, Leb and sLex binding isolate) became predominant a few months later. This led to inflammation, infiltration by lymphocytes [Fig. 4C, bluish due to hematoxyline/eosine (H/E)-staining], and microscopic detection of *H. pylori* infection (Fig. 4, E and F) (21). The virulent *H. pylori* infection led to strong sLex-antigen expression in the surface epithelium (Fig. 4C) and maintained expression in the deeper gastric glands (Fig. 4C); thus, a bi-layered expression mode supported strong binding of the *babA1A2* mutant to both regions (Fig. 4D). Bacterial pretreatment with sLex conjugate eliminated surface epithelial adherence and reduced gastric gland adherence by 88%. Thus, persistent *H. pylori* infection up-regulates expression of sLex antigens, which *H. pylori* can exploit for adherence to the surface epithelium.

Binding to Leb transgenic mouse gastric epithelium. We analyzed gastric mucosa of Leb mice for sLex antigen-dependent *H. pylori* adherence in situ [AIS, in (14)]. Pretreatment with the sLex conjugate reduced binding by *babA1A2*-mutant bacteria by more than 90% (Figs. 2A, vi, and 3D) but did not affect binding by its 17875 parent (Figs. 2A, v, and 3D). In comparison, pretreatment with soluble Leb antigen decreased adherence by >80% of the 17875 strain (Leb and sLex binding), whereas binding by the *babA1A2* mutant was not affected. mAb tests demonstrated sLex antigen in the gastric surface epithelium and pits of Leb mice (Fig. 2A, iv). That is, these mice are unusual in producing sialyl as well as Leb glycoconjugates

(even without infection), which each serve as receptors for *H. pylori*.

A finding that *H. pylori* pretreatment with Leb conjugate blocked its adherence to Leb mouse tissue, whereas sLex pretreatment did not, had been interpreted as indicating that *H. pylori* adherence is mediated solely by Leb antigen (22). However, because strain 17875 and its *babA1A2* mutant bound similar levels of soluble sLex conjugate (Fig. 3A), soluble Leb seems to interfere sterically with interactions between sLex-specific *H. pylori* adhesins and sLex receptors in host tissue (see also Fig. 1, E versus F). Because an excess of soluble sLex did not affect *H. pylori* binding to Leb receptors [Figs. 1H and 3C (in humans) and Figs. 2A, v, and 3D (in Leb-mice)], the steric hindrance is not reciprocal. Further tests showed that liquid phase binding is distinct. A 10-fold excess of soluble unlabeled Leb conjugate (3 μ g) along with 300 ng of 125 I-sLex conjugate did not affect strain 17875 binding to soluble sLex glycoconjugate.

Thus, soluble Leb conjugates interfere with sLex-mediated *H. pylori* binding specifically when the sLex moieties are constrained on surfaces. The lack of reciproc-

ity in these Leb-sLex interference interactions contributes to our model of receptor positioning on cell surfaces.

Saba identified. We identified the sLex-binding adhesin by "retagging." This technique exploits a receptor-bound multifunctional biotinylated crosslinker, and ultraviolet (UV) irradiation to mediate transfer of the biotin tag to the bound adhesin (4). Here, we added the crosslinker to sLex conjugate and used more UV exposure (14) than had been used to isolate the BabA adhesin (4) to compensate for the lower affinity of the sLex than the Leb-specific adhesin for cognate soluble receptors (Fig. 3B). Strain J99 was used, and a 66-kDa protein was recovered (Fig. 5A). Four peptides identified by mass spectrometry (MS)-matched peptides encoded by gene JHP662 in strain J99 (17) (gene HP0725 in strain 26695) (18). Two of the four peptides also matched those from the related gene JHP659 (HP0722) (86% protein level similarity to JHP662) (fig. S1).

To critically test if JHP662 or JHP659 encodes SabA, we generated *camR* insertion alleles of each gene in strain J99. Using radiolabeled glycoconjugates, we found that both sLex




Fig. 2. (A) The sLex antigen confers adherence of *H. pylori* to the transgenic Leb mouse gastric mucosa. H/E-stained biopsy of Leb mouse gastric mucosa (i). The 17875 strain (ii) and *babA1A2* mutant (iii) both adhered to the surface epithelium, which stained positive with the sLex mAb (iv). Adherence by the *babA1A2* mutant was lost (vi), while adherence by the 17875 strain was unperturbed (v), after pretreatment of the bacteria with soluble sLex antigen. (B) *H. pylori* binds to fucosylated gangliosides such as the sLex GSL. GSLs were separated on TLC and chemically stained (i) (14). Chromatograms were probed with sLex mAb (ii), the 17875 strain (iii), and the *babA1A2* mutant (iv). Lanes contained acid (i.e., sialylated) GSLs of calf brain, 40 μ g; acid GSLs of human neutrophil granulocytes, 40 μ g; sample number 2 after desialylation, 40 μ g; acid GSLs of adenocarcinoma, 40 μ g; sample number 4 after desialylation, 40 μ g; sdiLex GSL, 1 μ g; sLea GSL, 4 μ g; s(mono)Lex GSL, 4 μ g; and Leb GSL, 4 μ g. Binding results are summarized in table S1. (C) The high-affinity *H. pylori* GSL receptor was structurally identified by negative ion fast atom bombardment mass spectrometry. The molecular ion ($M-H^+$) at m/z 2174 indicates a GSL with one NeuAc, two fucoses, two *N*-acetylhexosamines, four hexoses, and d18:1-16:0; and the sequence NeuAcHex(Fuc)HexNAC-Hex(Fuc)HexNACHexHex was deduced. 1 H-NMR spectroscopy resolved the sdiLex antigen; NeuAc α 2.3Gal β 1.4(Fuc α 1.3)GlcNAC β 1.3Gal β 1.4(Fuc α 1.3)GlcNAC β 1.3Gal β 1.4Glc β 1Cer (14).

and sLea antigen-binding activity was abolished in the JHP662 (*sabA*) mutant, but not in the JHP659 (*sabB*) mutant. Thus, the SabA adhesin is encoded by JHP662 (HP0725). This gene encodes a 651-aa protein (70 kDa) and belongs to the large *hop* family of *H. pylori* outer membrane protein genes, including *babA* (17, 18). The *sabA* gene was then identified by PCR in six sLex-binding and six non-sLex-binding Swedish isolates, which suggests that *sabA* is present in the majority of *H. pylori* isolates (14).

Parallel studies indicated that the *sabA* inactivation did not affect adherence mediated by the BabA adhesin (Fig. 5B, *i*) and that pretreatment of the J99*sabA* mutant with soluble Leb antigen prevented its binding to gastric epithelium (Fig. 5B, *ii*). This implies that the SabA and BabA adhesins are organized and expressed as independent units.

Nevertheless, Leb conjugate pretreatment of J99 (BabA+ and SabA+) might have interfered with sLex antigen-mediated adherence (see Fig. 1E). To determine if this was a steric effect of the bulky glycoconjugate on exposure of SabA adhesin, single *babA* and *sabA* mutant J99 derivatives were used to further analyze Leb and sLex adherence (Fig. 5C, *i* to *iv*). Both single mutants adhered to the inflamed gastric epithelial samples, whereas the *babAsabA* (double) mutant was unable to bind this same tissue.

Instability of sLex binding. When screening for SabA mutants, we also analyzed single colony isolates from cultures of parent strain J99 (which binds both sLex and Leb antigens) (Fig. 3A), which indicated that 1% of colonies had spontaneously lost the ability to bind sLex. Similar results were obtained with strain 17875 (Fig. 3A) with an

OFF (non-sLex-binding) variant called 17875/Leb. In contrast, each of several hundred isolates tested retained Leb antigen-binding capacity.

Upstream and within the start of the *sabA* gene are poly T/CT tracts that should be hotspots for ON/OFF frameshift regulation [see HP0725 in (18)], which might underlie the observed instability of sLex-binding activity. Both strains' genome sequences, 26695 and J99, demonstrate CT repeats that suggest *sabA* to be out of frame (six and nine CTs, respectively) (17, 18). Four sLex-binding and four non-sLex-binding Swedish isolates, and in addition strain J99, were analyzed by PCR for CT repeats, and differences in length were found between strains. Ten CT repeats [as compared to nine in (17)] were

Fig. 3. *H. pylori* binds sialylated antigens. (A) *H. pylori* strains and mutants (14) were analyzed for binding to different ¹²⁵I-labeled soluble fucosylated and sialylated (Lewis) antigen-conjugates [RIA in (14)]. The bars give bacterial binding, and conjugates used are given in the diagram. (B) For affinity analyses (16), the sLex conjugate was added in titration series. The *babA1A2* mutant was incubated for 3 hours with the s(mono)Lex conjugate to allow for equilibrium in binding, which demonstrates an affinity (K_a) of 1×10^8 M⁻¹. (C) Adherence of strain 17875 (sLex and Leb-antigen binding) and *babA1A2* mutant to biopsy with inflammation and *H. pylori* infection, as scored by the number of bound bacteria after pretreatment with soluble Leb (Fig. 1, E and F) or sLex antigen (Fig. 1, H and I) (14). The Leb antigen reduced adherence of strain 17875 by >80%, whereas the sLex antigen abolished adherence of the *babA1A2* mutant. (D) Adherence of strain 17875 and *babA1A2* mutant to biopsy of Leb mouse gastric mucosa was scored by the number of bound bacteria after pretreatment with sLex conjugate. Adherence by the *babA1A2* mutant was abolished (Fig. 2A, *vi*), while adherence by strain 17875 was unperturbed (Fig. 2A, *v*). (E) Adherence of spontaneous phase variant strain 17875/Leb (Leb-antigen binding only in Fig. 3A) and *babA1A2* mutant was analyzed after pretreatment of histo-sections of human gastric mucosa with mAbs recognizing the Leb antigen or the sLex antigen (FH6), with efficient inhibition of adherence of both strain 17875/Leb and the *babA1A2* mutant, respectively. Value $P < 0.001$ (***), value $P < 0.01$ (**), value $P < 0.05$ (*).





Fig. 4. Infection induces expression of sLex antigens that serve as binding sites for *H. pylori* adherence. (A) and (B) came from a Rhesus monkey with healthy gastric mucosa. (C) to (F) came from the same Rhesus monkey 9 months after established reinfection with virulent clinical *H. pylori* isolates. Sections were analyzed with the sLex mAb (A) and (C) and by adherence in situ with the *babA1A2* mutant (B) and (D). In the healthy animal, both the sLex mAb staining and adherence of the *babA1A2* mutant is restricted to the deeper gastric glands [(A) and (B), arrows] [i.e., no mAb-staining of sLex antigens and no *babA1A2*-mutant bacteria present in the surface epithelium (A) and (B), arrowhead]. In contrast, in the *H. pylori*-infected and inflamed gastric mucosa, the sLex antigen is heavily expressed in the surface epithelium [(C), arrowhead with brownish immunostaining], in addition to the deeper gastric glands [(C), arrow]. The up-regulated sLex antigen now supports massive colocalized adherence of the *babA1A2* mutant in situ [(D), arrowhead] in addition to the constant binding to the deeper gastric glands [(B) and (D), arrow]. The established infection was visualized by Genta stain, where the *H. pylori* microbes were present in the surface epithelium [(E) and (F), arrowhead; (F) is at a higher magnification], while no microbes were detected in the deeper gastric glands [(E), arrow].

found in the sLex-binding J99 strain, which puts this ORF in frame, and could thus explain the ON bindings. These results further support the possibility for a flexible locus that confers ON/OFF binding properties (23).

Dynamics of sialylation during health and disease. Our analyses of *H. pylori* adherence provide insight into human responses to persistent infections, where gastritis and inflammation elicit appearance of sLex antigens and related sialylated carbohydrates in the stomach mucosa, which *cag*⁺ (virulent) *H. pylori* strains by adaptive mechanisms exploit as receptors in concert with the higher affinity binding to Leb. These two adherence modes may each benefit *H. pylori* by improving access to nutrients leached from damaged host tissues, even while increasing the risk of bactericidal damage by these same host defenses (Fig. 6). In the endothelial lining, sialylated Lewis-glycans serve as receptors for

selectin cell adhesion proteins that help guide leukocyte migration and thus regulate strength of response to infection or injury (24). For complementary attachment, the neutrophils themselves also express sialylated Lewis glycans, and such neutrophil glycans allow binding and infection by human granulocytic ehrlichiosis (25). However, sialylated glycoconjugates are low in healthy gastric mucosa but are expressed during gastritis. This sialylation was correlated with the capacity for SabA-dependent, but not BabA-dependent, *H. pylori* binding in situ. Our separate tests on Rhesus monkeys for experimental *H. pylori* infection confirmed that gastric epithelial sialylation is induced by *H. pylori* infection. In accord with this, high levels of sialylated glycoconjugates have been found in *H. pylori*-infected persons, which decreased after eradication of infection and resolution of gastritis (26). Thus, a sialy-

lated carbohydrate used to signal infection and inflammation and to guide defense responses can be co-opted by *H. pylori* as a receptor for intimate adherence.

High levels of sialylated glycoconjugates are associated with severe gastric disease, including dysplasia and cancer (27, 28). Sialylated glycoconjugates were similarly abundant in parietal cell-deficient mice (22). sLex was also present in the gastric mucosa of transgenic Leb mice (Fig. 2A). Whether this reflects a previously unrecognized pathology stemming from the abnormal (for mice) gastric synthesis of α 1.3/4FT or Leb antigen, or from fucosylation of already sialylated carbohydrates, is not known.

Persons with blood group O and “nonsecretor” phenotypes (lacking the ABO blood group-antigen synthesis in secretions such as saliva and milk) are relatively common (e.g., ~45 and ~15%, respectively, in Europe), and each group is at increased risk for peptic ulcer disease (29). The H1 and Leb antigens are abundant in the gastric mucosa of secretors (of blood group O) (6), but not in nonsecretors, where instead the sLex and sLea antigens are found (30). The blood group O-disease association was postulated to reflect the adherence of most *cag*⁺ *H. pylori* strains to H1 and Leb antigens (3). We now suggest that *H. pylori* adherence to sialylated glycoconjugates contributes similarly to the increased risk of peptic ulcer disease in nonsecretor individuals.

Adaptive and multistep-mediated attachment modes of *H. pylori*. Our findings that the SabA adhesin mediates binding to the structurally related sialyl-Lewis a antigen (sLea, in table S1) is noteworthy because sLea is an established tumor antigen (31) and marker of gastric dysplasia (27), which may further illustrate *H. pylori* capacity to exploit a full range of host responses to epithelial damage. The *H. pylori* BabA adhesin binds Leb antigen on glycoproteins (32), whereas its SabA adhesin binds sLex antigen in membrane glycolipids, which may protrude less from the cell surface. Thus, *H. pylori* adher-

Fig. 5. Retagging of SabA and identification of the corresponding gene, *sabA*. After contact-dependent retagging (of the *babA1A2* mutant) with crosslinker labeled sLex conjugate, the 66-kDa biotin-tagged adhesin SabA [(A), lane 1] was identified by SDS-polyacrylamide gel electrophoresis/streptavidin-blot, magnetic-bead-purified, and analyzed by MS for peptide masses (14). As a control, the Leb conjugate was used to retag 17875 bacteria, which visualized the 75-kDa BabA adhesin [(A), lane 2] (4). (B) The J99/JHP662::cam (*sabA*) mutant does not bind the sLex antigen but adheres to human gastric epithelium [(B), i], due to the BabA-adhesin, because pretreatment with soluble Leb antigen inhibited binding to the epithelium [(B), ii]. (C) The J99 wild-type strain (which binds both Leb and sLex antigens) [(C), i] and the J99 mutant (which binds Leb antigen only) [(C), ii] both exhibit strong adherence to the gastric mucosa. In comparison, the J99 *babA* mutant binds by lower-affinity interactions [(C), iii], while the J99 *sabAbabA* mutant, which is devoid of both adherence properties, does not bind to the gastric mucosa [(C), iv].





Fig. 6. *H. pylori* adherence in health and disease. This figure illustrates the proficiency of *H. pylori* for adaptive multistep mediated attachment. (A) *H. pylori* (in green) adherence is mediated by the Leb blood group antigen expressed in glycoproteins (blue chains) in the gastric surface epithelium (the lower surface) (3, 32). *H. pylori* uses BabA (green Y's) for strong and specific recognition of the Leb antigen (4). Most of the sLex-binding isolates also bind the Leb antigen (SabA, in red Y's). (B) During persistent infection and chronic inflammation (gastritis), *H. pylori* triggers the host tissue to retaylor the gastric mucosal glycosylation patterns to up-regulate the inflammation-associated sLex antigens (red host, triangles). Then, SabA (red Y structures) performs Selectin-mimicry by binding the sialyl-(di)-Lewis x/a glycosphingolipids, for membrane close



attachment and apposition. (C) At sites of vigorous local inflammatory response, as illustrated by the recruited activated white blood cell (orange “bleb”), those *H. pylori* subclones that have lost sLex-binding capacity due to ON/OFF frameshift mutation might have gained local advantage in the prepared escaping of intimate contact with (sialylated) lymphocytes or other defensive cells. Such adaptation of bacterial adherence properties and subsequent inflammation pressure could be major contributors to the extraordinary chronicity of *H. pylori* infection in human gastric mucosa.

ence during chronic infection might involve two separate receptor-ligand, interactions—one at “arm’s length” mediated by Leb, and another, more intimate, weaker, and sLex-mediated adherence. The weakness of the sLex-mediated adherence, and its metastable ON/OFF switching, may benefit *H. pylori* by allowing escape from sites where bactericidal host defense responses are most vigorous (Fig. 6C). In summary, we found that *H. pylori* infection elicits gastric mucosal sialylation as part of the chronic inflammatory response and that many virulent strains can exploit Selectin mimicry and thus “home in” on inflammation-activated domains of sialylated epithelium, complementing the baseline level of Leb receptors. The spectrum of *H. pylori* adhesin–receptor interactions is complex and can be viewed as adaptive, contributing to the extraordinary chronicity of *H. pylori* infection in billions of people worldwide, despite human genetic diversity and host defenses.

References and Notes

1. T. L. Cover *et al.*, in *Principles of Bacterial Pathogenesis*, E. A. Groisman, Ed. (Academic Press, New York, 2001), pp. 509–558.
2. M. Gerhard *et al.*, in *Helicobacter pylori: Molecular and Cellular Biology*, S. Suerbaum and M. Achtman, Eds. (Horizon Scientific Press, Norfolk, UK, 2001), chap. 12.
3. T. Borén *et al.*, *Science* **262**, 1892 (1993).
4. D. Ilver *et al.*, *Science* **279**, 373 (1998).
5. M. Hurlig, T. Borén, in preparation.
6. H. Clausen, S. i. Hakomori, *Vox Sang* **56**, 1 (1989).
7. T. Borén, P. Falk, *Science* **264**, 1387 (1994).
8. K. A. Karlsson, *Mol. Microbiol.* **29**, 1 (1998).
9. S. Censini *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **93**, 14648 (1996).
10. N. S. Akopyants *et al.*, *Mol. Microbiol.* **28**, 37 (1998).
11. E. D. Segal *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **96**, 14559 (1999).
12. M. Gerhard *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **96**, 12778 (1999).
13. J. L. Guruge *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **95**, 3925 (1998).
14. Strains and culture, adherence in situ (AIS), *H. pylori* overlay to TLC, isolation and identification of the s-di-Lex GSL, apical localization of sLex antigen expression (fig. S2), retagging and identification of SabA/sabA, alignment of JHP662/JHP659 (fig. S1), construction of adhesin gene mutants, analyses of sabA by PCR, RIA and Scatchard analyses, gastric biopsies from patients and monkeys analyzed for *H. pylori* binding activity and inflammation, and a summary of *H. pylori* binding to glycosphingolipids (table S1) are available as supporting online material.
15. P. G. Falk *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **92**, 1515 (1995).
16. G. Scatchard, *Ann. N.Y. Acad. Sci.* **51**, 660 (1949).
17. R. A. Alm *et al.*, *Nature* **397**, 176 (1999).
18. J. F. Tomb *et al.*, *Nature* **388**, 539 (1997).
19. S. i. Hakomori, in *Gangliosides and Cancer*, H. F. Oettgen, Ed. (VCH Publishers, New York, 1989), pp. 58–68.
20. J. F. Madrid *et al.*, *Histochemistry* **95**, 179 (1990).
21. A. Dubois *et al.*, *Gastroenterology* **116**, 90 (1999).
22. A. J. Syder *et al.*, *Mol. Cell* **3**, 263 (1999).
23. A. Arnqvist *et al.*, in preparation.
24. J. Alper, *Science* **291**, 2338 (2001).
25. M. J. Herron *et al.*, *Science* **288**, 1653 (2000).
26. H. Ota *et al.*, *Virchows Arch.* **433**, 419 (1998).
27. P. Sipponen, J. Lindgren, *Acta Pathol. Microbiol. Immunol. Scand.* **94**, 305 (1986).
28. M. Amado *et al.*, *Gastroenterology* **114**, 462 (1998).
29. P. Sipponen *et al.*, *Scand. J. Gastroenterol.* **24**, 581 (1989).
30. J. Sakamoto *et al.*, *Cancer Res.* **49**, 745 (1989).
31. J. L. Magnani *et al.*, *Science* **212**, 55 (1981).
32. P. Falk *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **90**, 2035 (1993).
33. We thank R. Clouse, H.M.T. El-Zimaity, D. Graham, and I. Anan for human biopsy material; J. Gordon and P. Falk for sections of Leb and FVB/N mouse stomach; L. Engstrand and A. Covacci for *H. pylori* strains; H. Clausen for the FH6 mAb; the Swedish NMR Centre, Göteborg University; P. Martin and Ö. Furberg for digital art/movie work; and J. Carlsson for critical reading of the manuscript. Supported by the Umeå University Biotechnology Fund, Swedish Society of Medicine/Bengt Ihre’s Fund, Swedish Society for Medical Research, Lion’s Cancer Research Foundation at Umeå University, County Council of Västerbotten, Neose Glycoscience Research Award Grant (T.B.), Swedish Medical Research Council [11218 (T.B.), 12628 (S.T.), 3967 and 10435 (K.-A.K.), 05975 (L.H.), and 04723 (T.W.)], Swedish Cancer Society [4101-B00-03XAB (T.B.) and 4128-B99-02XAB (S.T.)], SSF programs “Glycoconjugates in Biological Systems” (T.B., S.T., and K.-A.K.), and “Infection and Vaccinology” (T.B. and K.-A.K.), J. C. Kempe Memorial Foundation (J. M., L. F., and M.H.), Wallenberg Foundation (S.T. and K.-A.K.), Lundberg Foundation (K.-A.K.), ALF grant from Lund University Hospital (T.W.), and grants from the NIH [RO1 AI38166, RO3 AI49161, RO1 DK53727 (D.B.)] and from Washington University (P30 DK52574). These experiments were conducted according to the principles in the “Guide for the Care and Use of Laboratory Animals,” Institute of Laboratory Animal Resources, NRC, HHS/NIH Pub. No. 85–23. The opinions and assertions herein are private ones of the authors and are not to be construed as official or reflecting the views of the DOD, the Uniformed Services University of the Health Sciences, or the Defense Nuclear Agency.

Supporting Online Material

www.sciencemag.org/cgi/content/full/297/5581/573/DC1

Materials and Methods

Figs. S1 and S2

Tables S1 and S2

17 December 2001; accepted 17 June 2002

REPORTS

An Aligned Stream of Low-Metallicity Clusters in the Halo of the Milky Way

Suk-Jin Yoon* and Young-Wook Lee

One of the long-standing problems in modern astronomy is the curious division of Galactic globular clusters, the “Oosterhoff dichotomy,” according to the properties of their RR Lyrae stars. Here, we find that most of the lowest metallicity ($[Fe/H] < -2.0$) clusters, which are essential to an understanding of this phenomenon, display a planar alignment in the outer halo. This alignment, combined with evidence from kinematics and stellar population, indicates a captured origin from a satellite galaxy. We show that, together with the horizontal-branch evolutionary effect, the factor producing the dichotomy could be a small time gap between the cluster-formation epochs in the Milky Way and the satellite. The results oppose the traditional view that the metal-poor clusters represent the indigenous and oldest population of the Galaxy.

More than 60 years ago, Oosterhoff (1) discovered that Galactic globular clusters could be divided into two distinct groups according

Center for Space Astrophysics, Yonsei University, Seoul 120–749, Korea.

*To whom correspondence should be addressed. E-mail: sjyoon@csa.yonsei.ac.kr

to the mean period of type ab RR Lyrae variables ($\langle P_{ab} \rangle$). This dichotomy was one of the earliest indications of systematic difference among globular clusters, whose reality has been strengthened by subsequent investigations (2). Given that most characteristics of Galactic globular clusters appear to be distributed in a continuous way, it is unusual

that a quantity used to characterize variable stars falls into two rather well-defined classes. Moreover, the two groups are known to differ in metal abundance (3) and kinematic properties (4), which may indicate distinct origins. Whatever the reasons for the dichotomy, the question of whether the two groups originated under fundamentally different conditions is of considerable interest regarding the formation scenarios of the Galactic halo. Despite many efforts during the last decades, the origin of this phenomenon still lacks a convincing explanation.

Figure 1 shows the Oosterhoff dichotomy. Clusters belong to groups I and II if their values of $\langle P_{ab} \rangle$ fall near 0.55 and 0.65 days, respectively (5). Group I is more metal-rich than group II (3). Based on our horizontal-branch (HB) population models (6, 7), we have found that the presence of the relatively metal-rich ($-1.9 < [Fe/H] < -1.6$) clusters in group II (hereafter group II-a) can be understood by the sudden increase in $\langle P_{ab} \rangle$ at $[Fe/H] \approx -1.6$ (indicated by a blue line in Fig. 1). As $[Fe/H]$ decreases, HB stars get hotter (i.e., the HB morphology gets bluer), and there is a certain point at which the zero-age portion of the HB just crosses the